Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



麗珠醫藥集團股份有限公司 LIVZON PHARMACEUTICAL GROUP INC.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1513)

POLL RESULTS OF THE 2021 FOURTH EXTRAORDINARY GENERAL MEETING HELD ON FRIDAY, 10 DECEMBER 2021

References are made to the notice and circular (the "Circular") of the 2021 fourth extraordinary general meeting (the "EGM") of 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.*(the "Company") dated 18 November 2021. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

The Board is pleased to announce that the proposed resolution as set out in the notice of the EGM was duly passed by way of poll at the EGM held on 10 December 2021.

As at the record date of the EGM, the issued share capital of the Company was 937,628,616 shares (the "Shares") (comprising 624,392,999 A Shares and 313,235,617 H Shares). Joincare and its associates, directly or indirectly holding 418,878,625 shares of the Company (comprising of 255,513,953 A Shares and 163,364,672 H Shares), representing approximately 44.67% of the total issued share capital of the Company, were required to abstain from voting on Resolution 1 as set out in the notice of the EGM at the EGM pursuant to the Hong Kong Listing Rules as they are deemed to have material interest in Resolution 1. Accordingly, Shareholders (or authorized proxies) who hold 518,749,991 shares of the Company (comprising of 368,879,046 A Shares and 149,870,945 H Shares) were entitled to attend and vote on Resolution 1 proposed at the EGM.

Save as disclosed above, to the best of the Directors' knowledge, information and belief and having made all reasonable enquiries, there were no restrictions on any Shareholders for casting votes on the resolutions proposed at the EGM and none of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on the resolutions at the EGM. No Shareholders are required under the Hong Kong Listing Rules to abstain from voting on the resolutions at the EGM.

ATTENDANCE OF THE EGM

Set out below are the details of the Shareholders and authorized proxies present at the EGM:

Number of Shareholders and authorized proxies	55				
Including: Number of A Shareholders and authorized proxies					
Number of H Shareholders and authorized proxies	1				
Total number of Shares carrying voting rights (Shares)	105,565,996				
Including: Total number of A Shares carrying voting rights held by A					
Shareholders and authorized proxies (Shares)					
Total number of H Shares carrying voting rights held by H	55,578,305				
Shareholders and authorized proxies (Shares)					
Percentage of the total number of Shares carrying voting rights (%)	11.26%				
Including: Total number of Shares carrying voting rights held by A Shareholders and authorized					
proxies as a percentage of the total number of Shares carrying voting rights (%)					
Total number of Shares carrying voting rights held by H Shareholders and authorized	5.93%				
proxies as a percentage of the total number of Shares carrying voting rights (%)					

POLL RESULTS OF THE EGM- SEPCIAL RESOLUTION

				For		Against		Abstain	
No.	Resolution	Category of shares	Number of shares with voting rights held by Shareholders present at the meeting	Number of shares	Percentage (%) of number of shares with voting rights held by Shareholders present at the meeting	Number of shares	Percentage (%) of number of shares with voting rights held by Shareholders present at the meeting	Number of shares	Percentage (%) of number of shares with voting rights held by Shareholders present at the meeting
1.	To consider and approve a three-year continuing guarantee support framework agreement for 2022-2024 entered into between the Company and its controlling subsidiary Livzon MAB, the continuing connected transactions of provision of financing guarantees by the Company to Livzon MAB contemplated thereunder and the annual caps of the guarantees. Total A Shares	Total	105,565,996	105,553,913	99.9886%	7,083	0.0067%	5,000	0.0047%
		A Shares	49,987,691	49,975,608	99.9758%	7,083	0.0142%	5,000	0.0100%
		55,578,305	55,578,305	100.0000%	0	0.0000%	0	0.0000%	

As votes cast for the above special resolution were more than two-fourths of the valid voting rights of Shareholders (including authorized proxies) present at the EGM, the above special resolution was duly passed as a special resolution.

Grant Thornton (Special General Partnership), the auditor of the Company, acted as the scrutineer for the vote-

taking at the EGM. The Company's PRC legal advisors, D&S Law Firm (廣東德賽律師事務所), two

Shareholders' representatives and a representative of the supervisors of the Company also jointly acted as the

scrutineers for the vote-taking of the poll at the EGM.

LEGAL OPINION ISSUED BY LAWYERS

Delegated lawyers from D&S Law Firm witnessed the EGM and issued the "Legal Opinions of D&S Law Firm on

the EGM of Livzon Pharmaceutical Group Inc. (《廣東德賽律師事務所關於麗珠醫藥集團股份有限公司二零

二一年第四次臨時股東大會的法律意見書》)", certifying that: "The procedures for convening and holding the

EGM are in compliance with the requirements of laws, regulations and Articles of Association; the qualifications of

personnels who attended the EGM, the qualifications of the conveners, and the voting procedure of the EGM are

legal and effective; the voting results of the resolutions at the EGM, are legal and effective."

SPECIAL NOTICE

There was neither objection to the proposed resolutions of the EGM, nor changes to the resolutions of the previous

general meetings at the EGM.

By order of the Board

麗珠醫藥集團股份有限公司

Livzon Pharmaceutical Group Inc. *

Yang Liang

Company Secretary

Zhuhai, China

10 December 2021

As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (President) and

Mr. Xu Guoxiang (Vice Chairman and Vice President); the Non-Executive Directors of the Company are Mr. Zhu

Baoguo (Chairman), Mr. Tao Desheng (Vice Chairman), Mr. Qiu Qingfeng and Mr. Yu Xiong; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Tian Qiusheng, Mr. Wong Kam Wa, Mr. Luo Huiyuan

and Ms. Cui Lijie.

* For identification purpose only

4